LONG-TERM SAFETY EVALUATION OF THE 90-DAY EVERSENSE CGM SYSTEM IN THE USPOST APPROVAL SETTING

被引：0
|
作者：
Latif, K. [1 ]
Warren, M. [2 ]
Oiknine, R. [3 ]
Mann, P. [4 ]
Tweden, K. [4 ]
Kaufman, F. [5 ]
机构：
[1] AM Diabet & Endocrinol, Endocrinol, Bartlett, TN USA
[2] Phys East PA, Endocrinol, Greenville, NC USA
[3] Diabet & Endocrinol Specialists Inc, Endocrinol, Chesterfield, MO USA
[4] Senseonics Inc, Clin Sci, Germantown, MD USA
[5] Senseonics Inc, Med Affairs, Germantown, MD USA
来源：
DIABETES TECHNOLOGY & THERAPEUTICS | 2023年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
38
引用
收藏
页码：A156 / A156
页数：1
相关论文
共 50 条
  • [1] Long-term safety of the Eversense® CGM system: PMCF registry
    Kaufman, F. R.
    Tweden, K.
    Haridas, H.
    Carlson, G.
    [J]. DIABETOLOGIA, 2019, 62 : S434 - S435
  • [2] THE PROMISE STUDY: AN EVALUATION OF THE SAFETY AND ACCURACY OF THE NEXT GENERATION 180-DAY LONG-TERM IMPLANTABLE EVERSENSE CGM SYSTEM
    Garg, S.
    Liljenquist, D.
    Bode, B.
    Christiansen, M.
    Bailey, T.
    Brazg, R.
    Denham, D.
    Chang, A.
    Akturk, H.
    Dehennis, A.
    Tweden, K.
    Kaufman, F.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2021, 23 : A36 - A37
  • [3] Evaluation of accuracy and safety of the next generation 180-day long-term implantable Eversense CGM system: the PROMISE Study
    Garg, S.
    Liljenquist, D.
    Bode, B.
    Christiansen, M.
    Bailey, T.
    Brazg, R.
    Denham, D.
    Chang, A. R.
    Akturk, H.
    Dehennis, A.
    Tweden, K. S.
    Kaufman, F. R.
    [J]. DIABETOLOGIA, 2021, 64 (SUPPL 1) : 123 - 124
  • [4] Evaluation of the Next Generation 180-Day Long-Term Implantable Eversense CGM System: PROMISE Study
    Garg, Satish K.
    Liljenquist, David R.
    Bode, Bruce W.
    Christiansen, Mark P.
    Bailey, Timothy S.
    Brazg, Ronald L.
    Denham, Douglas S.
    Chang, Anna
    Akturk, Halis K.
    Dehennis, Andrew D.
    Tweden, Katherine
    Kaufman, Francine R.
    [J]. DIABETES, 2021, 70
  • [5] Post Market Clinical Follow-Up (PMCF) Registry to Demonstrate the Long Term Safety of the Eversense CGM System
    Carlson, Grace
    Tweden, Katherine S.
    Mdingi, Colleen
    Haridas, Haritha
    [J]. DIABETES, 2019, 68
  • [6] FEASIBILITY STUDY USE CASE AND PERFORMANCE OF A 90-DAY IMPLANTABLE CGM SYSTEM
    Chen, X.
    DeHennis, A.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2015, 17 : A31 - A31
  • [7] Predicting 90-day and long-term mortality in octogenarians undergoing radical cystectomy
    Michael Froehner
    Rainer Koch
    Matthias Hübler
    Ulrike Heberling
    Vladimir Novotny
    Stefan Zastrow
    Oliver W. Hakenberg
    Manfred P. Wirth
    [J]. BMC Urology, 18
  • [8] Predicting 90-day and long-term mortality in octogenarians undergoing radical cystectomy
    Froehner, Michael
    Koch, Rainer
    Huebler, Matthias
    Heberling, Ulrike
    Novotny, Vladimir
    Zastrow, Stefan
    Hakenberg, Oliver W.
    Wirth, Manfred P.
    [J]. BMC UROLOGY, 2018, 18
  • [9] Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study
    Garg, Satish K.
    Liljenquist, David
    Bode, Bruce
    Christiansen, Mark P.
    Bailey, Timothy S.
    Brazg, Ronald L.
    Denham, Douglas S.
    Chang, Anna R.
    Akturk, Halis
    Dehennis, Andrew
    Tweden, Katherine S.
    Kaufman, Francine R.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2022, 24 (02) : 84 - 92
  • [10] Safety of Microdose Dexamethasone Acetate in the Eversense Long-Term Implantable Continuous Glucose Monitoring System
    Kelley, E. L.
    Haridas, Haritha
    Lorenz, Carrie
    [J]. DIABETES, 2018, 67
12345